Search results
Author(s):
Rami Khayat
,
Andrew Pederzoli
,
William T Abraham
Added:
3 years ago
Heart failure is the only cardiovascular disease with increasing incidence and mortality.1 Approximately five million Americans have heart failure, with an annual incidence of 10 per 1,000 in individuals over 65 years of age, an already rising demographic segment of society. Heart failure is the most frequent Medicare diagnosis, with most of its cost related to hospitalizations.1,2 Identification…
View more
Author(s):
Jack Copeland
Added:
3 years ago
Mechanical circulatory support (MCS) devices are changing heart failure therapy. A spectrum of devices have become essential to the management of a variety of heart failure scenarios and, in the next few decades, this spectrum will expand and improve thousands of lives each year. The field has grown slowly and at considerable cost over the past 50 years but is now moving rapidly. Devices as small…
View more
Author(s):
Krisztina M Zsebo
,
Brian E Jaski
Added:
3 years ago
Despite important therapeutic improvements in pharmacological and device therapies, the prognosis for patients with advanced cardiovascular disease is poor, even with optimal pharmacological and device management. Heart failure continues to be a major cause of morbidity and mortality in the US. It is the leading medical cause of hospitalization and is expected to result in an estimated direct and…
View more
Author(s):
Cesare Rusconi
Added:
3 years ago
The pump function of the heart resides on two main abilities that allow the entire organism to cope with and face different physiological circumstances from sleep to intense physical exercise of sport activities:
a) diastolic function, defined as the ability of the ventricles to relax and to accept the normal stroke volume at the low pressures existing in the systemic and pulmonary veins; and
…
View more
THT 2024
Start date:
Mar 06, 2024
End date:
Mar 04, 2024
Event
Author(s):
Maria Rosa Costanzo
Added:
3 years ago
In the US, 90% of the one million annual hospitalizations for heart failure (HF) are due to volume overload.1,2 Hypervolemia contributes to HF progression and mortality. Guidelines recommend that therapy for HF patients be aimed at achieving euvolemia. Intravenous loop diuretics induce rapid diuresis that reduces lung congestion and dyspnea. However, the effectiveness of loop diuretics declines…
View more
Author(s):
Stuart D Katz
Added:
3 years ago
A recent study reported the clinical characteristics and outcomes of 43 non-edematous ambulatory patients with congestive heart failure, in whom clinical volume status was categorized by a direct measurement of blood volume by a radioisotope technique.1 Despite on-going treatment with high doses of loop diuretics and few physical signs of congestion, 65% of the subjects in this cohort were found…
View more
Author(s):
Sabu Thomas
,
Andrew J Boyle
,
Gary S Francis
Added:
3 years ago
Acute decompensated heart failure (ADHF) is a syndrome defined by worsening fatigue, dyspnea, or edema that results from deteriorating heart function and usually leads to hospital admission or unscheduled medical intervention.1 Among patients over 65 years of age it remains the leading cause of hospital admission (>1 million admissions per year in the US alone), has an exceptionally high rate…
View more
Author(s):
Giuseppe Rosano
Added:
1 year ago
In this short summary video, Prof Giuseppe Rosano (St George's University Hospital, UK) shares his highlights from Heart Failure 2022 and his thoughts on the next frontiers of heart failure management.
Recorded at Heart Failure2022, Madrid.
View more